ClinicalTrials.gg
CompletedNCT04027439Updated Sep 26, 2022Results posted

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

A Phase 2 interventional study of Part A: RPL554 and Part B: RPL554 in Pulmonary Disease, Chronic Obstructive, sponsored by Verona Pharma plc. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-26.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Merck & Co., Inc.

Enrollment
19th of 26
37 · median 89
Started
2018
with 1 other
Phase 2
18 of 26
none open now
Registered
15th of 26
by date

Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 19th largest by enrollment, is one of 2 that started in 2018, is one of 18 in phase 2, and was the 15th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Read the detailed description

The study will consist of two parts. Part A is a parallel group, placebo-controlled single dose study to ascertain the Pharmacokinetics (PK) profile, safety and bronchodilator effect of RPL554 administered via dry powder inhaler (DPI). Five of the 6 treatment arms will be double-blind and one will be single-blind (due to the different number of capsules administered). Part B is a placebo-controlled, complete block cross-over, repeat dose study to assess the bronchodilator effect of repeat doses of RPL554 delivered via a DPI.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
  2. For males, not to donate sperm and either be sexually abstinent or use as specified by the protocol. For females, be of non- or use a highly effective form of contraception
  3. 12-lead with heart rate between 45 and 90 beats per minute, ≤450 msec for males, and ≤ 470 msec for females, QRS interval ≤120 msec and no abnormality including morphology
  4. Capable of complying with all study restrictions and procedures including ability to use the DPI correctly.
  5. (BMI) between 18 and 35 kg/m2 (inclusive) with a minimum weight of 45 kg.
  6. diagnosis for 1 year [prior to screening
  7. Ability to perform acceptable and reproducible spirometry.
  8. Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating the following:

    • /Forced Vital Capacity (FVC) ratio of ≤0.70
    • FEV1 ≥40 % and ≤80% of predicted normal
    • ≥150 mL increase from pre-bronchodilator FEV1
  9. Clinically stable COPD in the 4 weeks prior to Screening and during the period between Screening and Part A.
  10. A chest X-ray showing no abnormalities, which are both clinically significant and unrelated to COPD.
  11. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  12. Current and former smokers with smoking history of ≥10 pack years. 14. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to dosing.

Exclusion criteria

Exclusion Criteria:

  1. A history of life-threatening including Intensive Care Unit admission and/or requiring intubation.
  2. COPD exacerbation requiring oral or parenteral , or lower respiratory tract infection requiring antibiotics, within 3 months of Screening or prior to Part A.
  3. A history of one or more hospitalizations for COPD or pneumonia within 6 months of Screening or prior to Part A.
  4. Intolerance or to tiotropium, olodaterol, atropine, ipratropium, or RPL554.
  5. Evidence of cor pulmonale or pulmonary hypertension.
  6. Other respiratory disorders
  7. Previous lung resection or lung reduction surgery.
  8. Use of therapy, including oral corticosteroids
  9. Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study.
  10. History of, or reason to believe a patient has, drug or alcohol abuse within the past 5 years.
  11. Received an experimental drug within 30 days or five half lives, whichever is longer.
  12. Patients with uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant.
  13. Documented cardiovascular disease, including any history of arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months prior to Screening
  14. Use of non-selective oral β-blockers.
  15. Major surgery (requiring general anesthesia) within 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
  16. A disclosed history or one known to the Investigator, of significant non compliance in previous studies or with prescribed medications.
  17. Required use of oxygen therapy, even on an occasional basis.
  18. History of of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
  19. Clinically significant abnormal values for safety laboratory tests (hematology, biochemistry, viral serology or urinalysis) at Screening, as determined by the Investigator. In particular, or aspartate aminotransferase cannot be more than twice the .
  20. Any other reason that the Investigator considers makes the patient unsuitable to participate.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    Part A: RPL554

    Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind

    Drug: Part A: RPL554 · Drug: Placebos

  • Active comparator
    Part B: RPL554

    Double-blind, placebo-controlled, complete block cross-over

    Drug: Part B: RPL554 · Drug: Placebos

Interventions

  • DrugEnsifentrineStudies of EnsifentrineEnsifentrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler

  • DrugEnsifentrineStudies of EnsifentrineEnsifentrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A

  • DrugPlacebos

    Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler. Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.

06

What researchers measure

Primary outcomes

  1. Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)

    RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose

    Time frame: Day 1

  2. Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)

    RPL554 Area under the curve at maximum concentration after a single dose

    Time frame: Day 1

  3. Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)

    RPL554 Plasma pharmacokinetics Half-life concentration after a single dose

    Time frame: Day 1

  4. Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)

    Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7

    Time frame: Day 7

Secondary outcomes

  1. Part A: Change From Baseline in Average FEV1 (Over 4 Hours)

    Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose

    Time frame: Day 1

  2. Part A: Change From Baseline in Average FEV1 (Over 12 Hours)

    Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose

    Time frame: Day 1

  3. Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)

    Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose

    Time frame: Day 1

  4. Part A: Safety and Tolerability / Hematology Safety Assessments

    number of patients with treatment-emergent hematology abnormal laboratory assessments

    Time frame: Day 1

  5. Part A: Safety and Tolerability / Blood Chemistry Safety Assessments

    number of patients with treatment-emergent blood chemistry abnormal laboratory assessments

    Time frame: Day 1

  6. Part A: Safety and Tolerability / Urinalysis Safety Assessments

    number of patients with treatment-emergent urinalysis abnormal laboratory assessments

    Time frame: Day 1

  7. Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate

    Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose

    Time frame: Day 1

  8. Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure

    number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp)

    Time frame: Day 1

  9. Part A: Safety and Tolerability / ECG - QTcF

    number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec

    Time frame: Day 1

  10. Part A: Safety and Tolerability / ECG - Heart Rate

    number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm

    Time frame: Day 1

  11. Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)

    Change from baseline in average FEV1 (over 4 hours) on Day 7

    Time frame: Day 7

  12. Part B: Change From Baseline in Average FEV1 (Over 12 Hours)

    Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7

    Time frame: Day 7

  13. Part B: Change From Baseline in Trough FEV1

    Change from Baseline FEV1 to Morning Trough FEV1 on Day 7

    Time frame: Day 7

  14. Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)

    Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose

    Time frame: Day 1

  15. Part B: Change From Baseline in Average FEV1 (Over 4 Hours)

    Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1

    Time frame: Day 1

  16. Part B: Change From Baseline in Average FEV1 (Over 12 Hours)

    Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1

    Time frame: Day 1

  17. Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)

    Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1

    Time frame: Day 1

  18. Part B: Safety and Tolerability / Hematology Safety Assessments

    number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group).

    Time frame: Day 7

  19. Part B: Safety and Tolerability / Blood Chemistry Safety Assessments

    number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).

    Time frame: Day 7

  20. Part B: Safety and Tolerability / Urinalysis Safety Assessments

    number of patients with treatment-emergent urinalysis abnormal laboratory assessments

    Time frame: Day 7

  21. Part B: Safety and Tolerability / ECG - QTcF

    number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec

    Time frame: Day 7

  22. Part B: Safety and Tolerability / ECG - Heart Rate

    number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm

    Time frame: Day 7

  23. Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate

    number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20

    Time frame: Day 7

  24. Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure

    number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20)

    Time frame: Day 7

  25. Part B: Change From Baseline in Peak Pulse Rate (Day 1)

    Change from baseline in peak pulse after first dose on Day 1

    Time frame: Day 1

  26. Part B: Change From Baseline in Peak Pulse Rate (Day 7)

    Change from baseline in peak pulse after morning dosing on Day 7

    Time frame: Day 7

  27. Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)

    RPL554 steady-state PK (tmax) after morning dose on Day 7

    Time frame: Day 7

  28. Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)

    RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7

    Time frame: Day 7

  29. Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)

    RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7

    Time frame: Day 7

07

Results

Posted May 7, 2021

Participant flow

37 subjects enrolled for Part A and anticipated to continue into Part B.

Part A (R, PC, PG) Single Dose
Participant flow — Part A (R, PC, PG) Single Dose
Milestone0.15 mg/Part A0.50 mg/Part A1.5 mg/Part A3 mg/Part A6 mg/Part APlacebo/Part ASeq. 1/Part BSeq. 2/Part BSeq. 3/Part BSeq. 4/Part BSeq. 5/Part BSeq. 6/Part BSeq. 7/Part BSeq. 8/Part BSeq. 9/Part BSeq. 10/Part B
Started6676660000000000
Completed6676660000000000
Not completed0000000000000000
Part B (R, PC, CO) Twice Daily for 7 Day
Participant flow — Part B (R, PC, CO) Twice Daily for 7 Day
Milestone0.15 mg/Part A0.50 mg/Part A1.5 mg/Part A3 mg/Part A6 mg/Part APlacebo/Part ASeq. 1/Part BSeq. 2/Part BSeq. 3/Part BSeq. 4/Part BSeq. 5/Part BSeq. 6/Part BSeq. 7/Part BSeq. 8/Part BSeq. 9/Part BSeq. 10/Part B
Started0000004343433443
Completed0000004143433443
Not completed0000000200000000

Outcome measures

PrimaryPart A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)

RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose

Time frame:
Day 1
Reported as:
Geometric mean · h*pg/mL
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)
h*pg/mL0.15 mg0.50 mg1.5 mg3 mg6 mg
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)260 ± 53.5472 ± 106.72210 ± 62.34160 ± 47.29730 ± 62.3
PrimaryPart A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)

RPL554 Area under the curve at maximum concentration after a single dose

Time frame:
Day 1
Reported as:
Geometric mean · h*pg/mL
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)
h*pg/mL0.15 mg0.50 mg1.5 mg3 mg6 mg
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)222 ± 55.5495 ± 128.22680 ± 56.54920 ± 44.511600 ± 68.3
PrimaryPart A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)

RPL554 Plasma pharmacokinetics Half-life concentration after a single dose

Time frame:
Day 1
Reported as:
Geometric mean · h
Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)
h0.15 mg0.50 mg1.5 mg3 mg6 mg
Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)3.595.39 ± 28.77.48 ± 43.36.65 ± 33.66.66 ± 25.4
PrimaryPart B: Change From Baseline in Peak FEV1 (Over 4 Hours)

Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7

Time frame:
Day 7
Reported as:
Mean · L
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)0.220 ± 0.15930.293 ± 0.24110.298 ± 0.23550.378 ± 0.21820.118 ± 0.1437
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.186 · 95% CI 1.138 to 1.235
  • 1.5 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.134 · 95% CI 1.088 to 1.181
  • 0.50 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.134 · 95% CI 1.089 to 1.181
  • 0.15 mg vs Placebo · ANCOVA · p = 0.0001 · Contrast ratio: 1.084 · 95% CI 1.041 to 1.128
SecondaryPart A: Change From Baseline in Average FEV1 (Over 4 Hours)

Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose

Time frame:
Day 1
Reported as:
Mean · L
Part A: Change From Baseline in Average FEV1 (Over 4 Hours)
L0.15 mg0.50 mg1.5 mg3 mg6 mgPlacebo
Part A: Change From Baseline in Average FEV1 (Over 4 Hours)0.109 ± 0.03800.213 ± 0.12260.326 ± 0.2490.337 ± 0.18310.334 ± 0.11700.040 ± 0.0517
Statistical analysis
  • 6 mg vs Placebo · ANCOVA · p = 0.0004 · Contrast ratio: 1.228 · 95% CI 1.105 to 1.365
  • 3 mg vs Placebo · ANCOVA · p = 0.0004 · Contrast ratio: 1.228 · 95% CI 1.104 to 1.365
  • 1.5 mg vs Placebo · ANCOVA · p = 0.0012 · Contrast ratio: 1.196 · 95% CI 1.080 to 1.326
  • 0.50 mg vs Placebo · ANCOVA · p = 0.0348 · Contrast ratio: 1.121 · 95% CI 1.009 to 1.246
  • 0.15 mg vs Placebo · ANCOVA · p = 0.3106 · Contrast ratio: 1.055 · 95% CI 0.949 to 1.172
SecondaryPart A: Change From Baseline in Average FEV1 (Over 12 Hours)

Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose

Time frame:
Day 1
Reported as:
Mean · L
Part A: Change From Baseline in Average FEV1 (Over 12 Hours)
L0.15 mg0.50 mg1.5 mg3 mg6 mgPlacebo
Part A: Change From Baseline in Average FEV1 (Over 12 Hours)0.045 ± 0.03840.113 ± 0.17030.214 ± 0.21720.243 ± 0.27150.176 ± 0.0481-0.011 ± 0.0749
Statistical analysis
  • 6 mg vs Placebo · ANCOVA · p = 0.0208 · Contrast ratio: 1.154 · 95% CI 1.024 to 1.301
  • 3 mg vs Placebo · ANCOVA · p = 0.0041 · Contrast ratio: 1.200 · 95% CI 1.064 to 1.353
  • 1.5 mg vs Placebo · ANCOVA · p = 0.0108 · Contrast ratio: 1.167 · 95% CI 1.039 to 1.311
  • 0.50 mg vs Placebo · ANCOVA · p = 0.1641 · Contrast ratio: 1.087 · 95% CI 0.965 to 1.225
SecondaryPart A: Change From Baseline in Peak FEV1 (Over 4 Hours)

Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose

Time frame:
Day 1
Reported as:
Mean · L
Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)
L0.15 mg0.50 mg1.5 mg3 mg6 mgPlacebo
Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)0.203 ± 0.06460.298 ± 0.12800.429 ± 0.25040.468 ± 0.21350.452 ± 0.13820.135 ± 0.0922
Statistical analysis
  • 6 mg vs Placebo · ANCOVA · p = 0.0005 · Contrast ratio: 1.229 · 95% CI 1.102 to 1.369
  • 3 mg vs Placebo · ANCOVA · p = 0.0005 · Contrast ratio: 1.231 · 95% CI 1.104 to 1.372
  • 1.5 mg vs Placebo · ANCOVA · p = 0.0022 · Contrast ratio: 1.188 · 95% CI 1.070 to 1.320
  • 0.50 mg vs Placebo · ANCOVA · p = 0.0658 · Contrast ratio: 1.106 · 95% CI 0.993 to 1.233
SecondaryPart A: Safety and Tolerability / Hematology Safety Assessments

number of patients with treatment-emergent hematology abnormal laboratory assessments

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / Blood Chemistry Safety Assessments

number of patients with treatment-emergent blood chemistry abnormal laboratory assessments

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / Urinalysis Safety Assessments

number of patients with treatment-emergent urinalysis abnormal laboratory assessments

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / Supine Vital Signs - Pulse Rate

Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / Supine Vital Signs - Blood Pressure

number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp)

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / ECG - QTcF

number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart A: Safety and Tolerability / ECG - Heart Rate

number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart B: Change From Baseline in Average FEV1 (Over 4 Hrs)

Change from baseline in average FEV1 (over 4 hours) on Day 7

Time frame:
Day 7
Reported as:
Mean · L
Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)0.100 ± 0.14300.176 ± 0.22530.184 ± 0.21760.244 ± 0.19530.017 ± 0.1526
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.183 · 95% CI 1.134 to 1.234
  • 1.5 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.140 · 95% CI 1.092 to 1.190
  • 0.50 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.131 · 95% CI 1.084 to 1.180
  • 0.15 mg vs Placebo · ANCOVA · p = 0.0004 · Contrast ratio: 1.080 · 95% CI 1.036 to 1.126
SecondaryPart B: Change From Baseline in Average FEV1 (Over 12 Hours)

Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7

Time frame:
Day 7
Reported as:
Mean · L
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)0.052 ± 0.17590.106 ± 0.21250.096 ± 0.17960.163 ± 0.16790.016 ± 0.1455
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.123 · 95% CI 1.078 to 1.169
  • 1.5 mg vs Placebo · ANCOVA · p = 0.0004 · Contrast ratio: 1.078 · 95% CI 1.035 to 1.122
  • 0.50 mg vs Placebo · ANCOVA · p = 0.0002 · Contrast ratio: 1.081 · 95% CI 1.039 to 1.125
  • 0.15 mg vs Placebo · ANCOVA · p = 0.0437 · Contrast ratio: 1.041 · 95% CI 1.001 to 1.083
SecondaryPart B: Change From Baseline in Trough FEV1

Change from Baseline FEV1 to Morning Trough FEV1 on Day 7

Time frame:
Day 7
Reported as:
Mean · L
Part B: Change From Baseline in Trough FEV1
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Trough FEV1-0.036 ± 0.13320.031 ± 0.18210.020 ± 0.18380.030 ± 0.1539-0.067 ± 0.1577
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = 0.0006 · Contrast ratio: 1.087 · 95% CI 1.038 to 1.139
  • 1.5 mg vs Placebo · ANCOVA · p = 0.0010 · Contrast ratio: 1.083 · 95% CI 1.034 to 1.135
  • 0.50 mg vs Placebo · ANCOVA · p = 0.0002 · Contrast ratio: 1.096 · 95% CI 1.047 to 1.149
  • 0.15 mg vs Placebo · ANCOVA · p = 0.0971 · Contrast ratio: 1.039 · 95% CI 0.993 to 1.088
SecondaryPart B: Change From Baseline in Peak FEV1 (Over 4 Hours)

Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose

Time frame:
Day 1
Reported as:
Mean · L
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)0.310 ± 0.13820.332 ± 0.21810.401 ± 0.17050.404 ± 0.18670.188 ± 0.1267
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.145 · 95% CI 1.106 to 1.185
  • 1.5 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.148 · 95% CI 1.109 to 1.189
  • 0.50 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.099 · 95% CI 1.062 to 1.137
  • 0.15 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.088 · 95% CI 1.052 to 1.126
SecondaryPart B: Change From Baseline in Average FEV1 (Over 4 Hours)

Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1

Time frame:
Day 1
Reported as:
Mean · L
Part B: Change From Baseline in Average FEV1 (Over 4 Hours)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Average FEV1 (Over 4 Hours)0.201 ± 0.11800.227 ± 0.20260.268 ± 0.15180.285 ± 0.15970.079 ± 0.1081
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.150 · 95% CI 1.113 to 1.189
  • 1.5 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.146 · 95% CI 1.109 to 1.185
  • 0.50 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.107 · 95% CI 1.071 to 1.144
  • 0.15 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.094 · 95% CI 1.059 to 1.130
SecondaryPart B: Change From Baseline in Average FEV1 (Over 12 Hours)

Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1

Time frame:
Day 1
Reported as:
Mean · L
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
L0.15 mg0.50 mg1.5 mg3 mgPlacebo
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)0.101 ± 0.13140.139 ± 0.19210.135 ± 0.16550.182 ± 0.15360.044 ± 0.1073
Statistical analysis
  • 3 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.103 · 95% CI 1.066 to 1.141
  • 1.5 mg vs Placebo · ANCOVA · p = <0.0001 · Contrast ratio: 1.078 · 95% CI 1.042 to 1.116
  • 0.50 mg vs Placebo · ANCOVA · p = 0.0002 · Contrast ratio: 1.067 · 95% CI 1.032 to 1.104
  • 0.15 mg vs Placebo · ANCOVA · p = 0.0066 · Contrast ratio: 1.048 · 95% CI 1.013 to 1.084
SecondaryPart B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)

Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1

Time frame:
Day 1
Reported as:
Median · mins
Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)
mins0.15 mg0.50 mg1.5 mg3 mg
Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)13.0 (3 to 120)15 (3 to 120)15 (4 to 125)13 (4 to 120)
SecondaryPart B: Safety and Tolerability / Hematology Safety Assessments

number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group).

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / Blood Chemistry Safety Assessments

number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / Urinalysis Safety Assessments

number of patients with treatment-emergent urinalysis abnormal laboratory assessments

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / ECG - QTcF

number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / ECG - Heart Rate

number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / Supine Vital Signs - Pulse Rate

number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Safety and Tolerability / Supine Vital Signs - Blood Pressure

number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20)

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: Change From Baseline in Peak Pulse Rate (Day 1)

Change from baseline in peak pulse after first dose on Day 1

Time frame:
Day 1

Results for this outcome have not been posted.

SecondaryPart B: Change From Baseline in Peak Pulse Rate (Day 7)

Change from baseline in peak pulse after morning dosing on Day 7

Time frame:
Day 7

Results for this outcome have not been posted.

SecondaryPart B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)

RPL554 steady-state PK (tmax) after morning dose on Day 7

Time frame:
Day 7
Reported as:
Median · h
Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)
h0.15 mg0.50 mg1.5 mg3 mg
Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)1.000 (0.417 to 2.000)1.000 (0.000 to 3.917)1.000 (0.000 to 2.000)1.000 (0.000 to 2.000)
SecondaryPart B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)

RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7

Time frame:
Day 7
Reported as:
Geometric mean · pg/mL
Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)
pg/mL0.15 mg0.50 mg1.5 mg3 mg
Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)68.7 ± 41.6237 ± 47.4591 ± 71.11240 ± 41.4
SecondaryPart B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)

RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7

Time frame:
Day 7
Reported as:
Geometric mean · h*pg/mL
Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)
h*pg/mL0.15 mg0.50 mg1.5 mg3 mg
Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)263 ± 56.21240 ± 52.33070 ± 73.66460 ± 49.9

Adverse events

Collected over Part A: 24 hours. Part B: Approximately 70 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 0.15 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: 0.50 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: 1.5 mg0/7 (0%)0/7 (0%)1/7 (14.3%)
Part A: 3 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: 6 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: Placebo0/6 (0%)0/6 (0%)0/6 (0%)
Part B: 0.15 mg0/35 (0%)0/35 (0%)3/35 (8.6%)
Part B: 0.50 mg0/33 (0%)0/33 (0%)9/33 (27.3%)
Part B: 1.5 mg0/32 (0%)0/32 (0%)4/32 (12.5%)
Part B: 3 mg0/33 (0%)0/33 (0%)4/33 (12.1%)
Part B: Placebo0/32 (0%)0/32 (0%)5/32 (15.6%)
Most frequent other events
Most frequent other events
EventPart A: 0.15 mgPart A: 0.50 mgPart A: 1.5 mgPart A: 3 mgPart A: 6 mgPart A: PlaceboPart B: 0.15 mgPart B: 0.50 mgPart B: 1.5 mgPart B: 3 mgPart B: Placebo
Atrioventricular block first degreeCardiac disorders0/60/61/70/60/60/60/350/330/320/330/32
HypertensionVascular disorders0/60/60/70/60/60/61/352/332/321/332/32
Blood thyroid stimulating hormone increasedInvestigations0/60/60/70/60/60/60/351/332/321/330/32
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/60/60/70/60/60/60/351/330/320/332/32
Urinary tract infectionInfections and infestations0/60/60/70/60/60/61/352/330/321/330/32
Blood creatine phosphokinase increasedInvestigations0/60/60/70/60/60/60/351/330/321/331/32
Eye contusionInjury, poisoning and procedural complications0/60/60/70/60/60/60/351/330/320/330/32
Diabetes mellitusMetabolism and nutrition disorders0/60/60/70/60/60/60/351/330/320/330/32
Ear infectionInfections and infestations0/60/60/70/60/60/61/350/330/320/330/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.15 mg0.50 mg1.5 mg3 mg6 mgPlaceboTotal
Mean61.7 ± 10.1558.3 ± 3.5663.7 ± 6.6852.7 ± 3.8859.3 ± 7.8160.8 ± 8.8059.5 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)0.15 mg0.50 mg1.5 mg3 mg6 mgPlaceboTotal
Female45352423
Male21414214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.15 mg0.50 mg1.5 mg3 mg6 mgPlaceboTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0020002
White66566635
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)0.15 mg0.50 mg1.5 mg3 mg6 mgPlaceboTotal
United States66766637
08

Study locations

1 site
  • VitaLink Research -- Union
    Union, South Carolina 29379, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2019, 5 months.

Results were first posted in May 2021, 1 year 11 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2019
First posted
Jul 22, 2019
StartActual
Dec 10, 2018
Primary completionActual
May 23, 2019
CompletionActual
May 23, 2019
Results first posted
May 7, 2021
Last update
Sep 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04027439
Lead sponsor
Verona Pharma plc
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Dec 10, 2018
Primary completion
May 23, 2019
Completion
May 23, 2019
Results posted
May 7, 2021
Last update
Sep 26, 2022

Study contacts

J Boscia, MD
principal investigator · Vitalink Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion